Financials in GBp. Standardized financial statements.
A compact view of how Oxford Biomedica plc turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | £168.74M | £128.80M | £89.54M | £139.99M | £142.80M | £87.73M | £64.06M | £66.78M | £37.59M | £27.78M |
| Revenue Growth? | +31.0% | +43.8% | -36.0% | -2.0% | +62.8% | +36.9% | -4.1% | +77.6% | +35.3% | 0.0% |
| Cost of Revenue? | £102.76M | £75.78M | £49.81M | £70.81M | £60.16M | £41.66M | £35.72M | £22.76M | £18.44M | £11.84M |
| Gross Profit? | £65.98M | £53.02M | £39.73M | £69.18M | £82.64M | £46.07M | £28.34M | £44.02M | £19.15M | £15.94M |
| Gross Margin? | +39.1% | +41.2% | +44.4% | +49.4% | +57.9% | +52.5% | +44.2% | +65.9% | +50.9% | +57.4% |
| Operating Expenses? | £99.52M | £92.40M | £223.90M | £120.74M | £61.71M | £50.94M | £40.92M | £36.08M | £27.11M | £27.25M |
| Operating Income? | -£33.54M | -£39.38M | -£184.17M | -£30.22M | £20.77M | -£5.69M | -£12.58M | £8.00M | -£5.67M | -£11.31M |
| EBITDA? | -£33.54M | -£14.33M | -£148.62M | -£10.80M | £33.22M | £3.92M | -£9.60M | £12.29M | £2.03M | -£11.71M |
| Income Before Tax | -£31.94M | -£47.27M | -£188.53M | -£45.98M | £19.88M | -£6.57M | -£20.89M | £5.01M | -£11.76M | -£20.31M |
| Income Tax Expense | -£1.29M | £1.34M | -£4.37M | -£817,000 | £869,000 | -£327,000 | -£4.82M | -£2.53M | -£2.74M | -£3.67M |
| Net Income? | -£30.13M | -£43.19M | -£157.49M | -£39.16M | £19.01M | -£6.25M | -£16.07M | £7.54M | -£9.02M | -£16.64M |
| EPS? | £-0.27 | £-0.42 | £-1.63 | £-0.41 | £0.23 | £-0.08 | £-0.22 | £0.11 | £-0.15 | £-0.30 |
| Diluted EPS? | £-0.27 | £-0.42 | £-1.63 | £-0.41 | £0.22 | £-0.08 | £-0.22 | £0.11 | £-0.15 | £-0.30 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality